tolvaptan has been researched along with Chronic Kidney Failure in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 11 (47.83) | 2.80 |
| Authors | Studies |
|---|---|
| Schmitt, R; Wulfmeyer, VC | 1 |
| Chan, T; de Zoysa, JR; van der Merwe, W | 1 |
| Agraz-Pamplona, I; Alvarez, C; Álvarez-Mora, MI; Bastida, C; Blasco, M; Broseta, JJ; Furlano, M; Nicolau, C; Piñeiro, GJ; Poch, E; Quintana, LF; Rodríguez-Espinosa, D; Ruiz, C; Sánchez-Baya, M; Torra-Balcells, R | 1 |
| Barnett, CL; Mader, G; Mladsi, D; Oberdhan, D; Purser, M; Sanon, M; Seliger, S; Watnick, T | 1 |
| Ackley, W; Dahl, NK; Park, M | 1 |
| Patel, SJ; Sadowski, CK | 1 |
| Amicone, M; Angelucci, V; Pisani, A; Riccio, E | 1 |
| Fukuhara, H; Furukawa, T; Higashihara, E; Horie, S; Kaname, S; Kawano, H; Muto, S; Taguchi, S; Tambo, M; Yamaguchi, T; Yokoyama, K; Yoshioka, T | 1 |
| Collard, L; Dachy, A; Ghuysen, MS; Jouret, F; Krzesinski, JM; Mekahli, D; Seghaye, MC | 1 |
| Akabane, M; Ishii, Y; Miki, K; Nakamura, Y; Yokoyama, T | 1 |
| Amicone, M; Buonanno, P; Capuano, I; Pisani, A; Riccio, E | 1 |
| Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Koch, G; McQuade, RD; Ouyang, J; Perrone, RD; Sergeyeva, O; Torres, VE | 1 |
| Akashi, YJ; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y; Tominaga, N | 1 |
| Bennett, H; Hamilton, K; McEwan, P; O'Reilly, K | 1 |
| Chertow, GM; Erickson, KF; Goldhaber-Fiebert, JD | 1 |
| Chida, M; Ito, S; Kiyomoto, H; Kodama, M; Koizumi, K; Miyazaki, M; Mori, T; Oba, I; Ogawa, S; Saito, M; Sato, H; Shimanuki, M; Tanno, M | 1 |
| Aihara, M; Fujiki, H; Hattori, K; Ishikawa, M; Mizuguchi, H; Nagano, K; Ohmoto, K; Yamamura, Y | 1 |
| Kawasaki, H; Mukae, Y; Nakayama, Y; Sato, M | 1 |
| Cornec-Le Gall, E; Le Meur, Y | 1 |
| Asai, K; Furuta, S; Hiramatsu, T; Hobo, A; Ozeki, A; Saka, M | 1 |
| Stiefelhagen, P | 1 |
| Burtey, S | 1 |
| Edelstein, CL | 1 |
5 review(s) available for tolvaptan and Chronic Kidney Failure
| Article | Year |
|---|---|
[What is evidence-based in the treatment of autosomal dominant polycystic kidney disease?]
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2021 |
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2023 |
Therapeutic advances in ADPKD: the future awaits.
Topics: Animals; Apoptosis; Calcium; Humans; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan; TRPP Cation Channels | 2022 |
[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Management; Disease Models, Animal; Drugs, Investigational; Epithelial Cells; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Mice; Models, Biological; Multicenter Studies as Topic; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases | 2014 |
[Slow the pace of renal failure in autosomal dominant polycystic kidney disease: hopes and disappointments].
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Comorbidity; Cyclic AMP; DNA Mutational Analysis; Drugs, Investigational; Genetic Carrier Screening; Histone Deacetylases; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Metformin; Mice; Polycystic Kidney, Autosomal Dominant; Prognosis; Rats; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases; TRPP Cation Channels; Valproic Acid | 2011 |
4 trial(s) available for tolvaptan and Chronic Kidney Failure
| Article | Year |
|---|---|
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Bilirubin; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Young Adult | 2017 |
Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Kidney Failure, Chronic; Male; Potassium; Prospective Studies; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2017 |
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Disease Management; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Polycystic Kidney, Autosomal Dominant; Proof of Concept Study; Reproducibility of Results; Time; Tolvaptan | 2019 |
The Vasopressin 2 Receptor Antagonist Tolvaptan Improves Nutrition and Inflammatory States in Peritoneal Dialysis Patients with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; C-Reactive Protein; Cohort Studies; Diabetes Complications; Female; Historically Controlled Study; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nutritional Status; Peritoneal Dialysis; Tolvaptan | 2015 |
14 other study(ies) available for tolvaptan and Chronic Kidney Failure
| Article | Year |
|---|---|
Delay in funding of tolvaptan for polycystic kidney disease in Aotearoa New Zealand.
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Native Hawaiian or Other Pacific Islander; New Zealand; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2022 |
Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment.
Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2023 |
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Time Factors; Tolvaptan | 2022 |
An update on treatments for autosomal dominant polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2023 |
[Tolvaptan in ADPKD: a turning point or an unsustainable therapy? One year of "real life" experience].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Feasibility Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Medication Adherence; Middle Aged; Patient Satisfaction; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Quality of Life; Time Factors; Tolvaptan; Young Adult | 2020 |
Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Topics: Adult; Aged; Body Height; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Patient Selection; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Reference Values; Retrospective Studies; Risk Assessment; ROC Curve; Severity of Illness Index; Time Factors; Tolvaptan | 2020 |
[Autosomal dominant polycystic kidney disease : a pediatric perspective].
Topics: Adult; Animals; Child; Disease Progression; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan | 2020 |
Usefulness of Tolvaptan for the Postoperative Control After Kidney Transplantation in a Patient With Cardiac Hypofunction: A Case Report.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Cardiac Output, Low; Heart Failure; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Myocardial Infarction; Postoperative Complications; Renal Dialysis; Tolvaptan | 2021 |
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Benzazepines; Cost-Benefit Analysis; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Life Expectancy; Male; Markov Chains; Middle Aged; Polycystic Kidney, Autosomal Dominant; Quality-Adjusted Life Years; Tolvaptan | 2013 |
Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Fluids; Diuretics; Female; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Osmolar Concentration; Peritoneal Dialysis; Tolvaptan; Urine | 2013 |
Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
Topics: Acute-Phase Proteins; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Kidney; Kidney Failure, Chronic; Lipocalin-2; Lipocalins; Magnetic Resonance Imaging; Male; Mice; Oncogene Proteins; Organ Size; Polycystic Kidney Diseases; Signal Transduction; Time Factors; Tolvaptan | 2014 |
[Clinical effects of tolvaptan for patients with stage 4-5 chronic kidney disease in cardiac surgery].
Topics: Aged; Aged, 80 and over; Benzazepines; Cardiac Surgical Procedures; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Receptors, Vasopressin; Tolvaptan | 2014 |
[Heart and kidney failure combined. Trouble seldom comes alone].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Combined Modality Therapy; Comorbidity; Diagnosis, Differential; Diuretics; Edema, Cardiac; General Adaptation Syndrome; Heart Failure; Humans; Hyperparathyroidism, Secondary; Iron; Kidney Failure, Chronic; Renin-Angiotensin System; Tolvaptan | 2011 |
Therapeutic interventions for autosomal dominant polycystic kidney disease.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child; Clinical Trials as Topic; Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Octreotide; Polycystic Kidney, Autosomal Dominant; Protein Kinases; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases | 2008 |